title: Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010.
abstract: The United States (US) influenza A (H1N1) 2009 monovalent (2009-H1N1) vaccination program began in October 2009. Reports to the vaccine adverse event reporting system (VAERS), a US spontaneous reporting system, were reviewed to identify potential rare events or unusual adverse event (AE) patterns after 2009-H1N1 vaccination. The adverse event profile after 2009-H1N1 vaccine in VAERS (∼10,000 reports) was consistent with that of seasonal influenza vaccines, although the reporting rate was higher after 2009-H1N1 than seasonal influenza vaccines, this may be, at least in part, a reflection of stimulated reporting. Death, Guillain-Barré syndrome and anaphylaxis reports after 2009-H1N1 vaccination were rare (each <2 per million doses administered).
authors.affiliation: Immunization Safety Office, Division of Health Care Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. bno1@cdc.gov
authors.forename: Claudia
authors.initials: C
authors.lastname: Vellozzi
authors.forename: Karen R
authors.initials: KR
authors.lastname: Broder
authors.forename: Penina
authors.initials: P
authors.lastname: Haber
authors.forename: Alice
authors.initials: A
authors.lastname: Guh
authors.forename: Michael
authors.initials: M
authors.lastname: Nguyen
authors.forename: Maria
authors.initials: M
authors.lastname: Cano
authors.forename: Paige
authors.initials: P
authors.lastname: Lewis
authors.forename: Michael M
authors.initials: MM
authors.lastname: McNeil
authors.forename: Marthe
authors.initials: M
authors.lastname: Bryant
authors.forename: James
authors.initials: J
authors.lastname: Singleton
authors.forename: David
authors.initials: D
authors.lastname: Martin
authors.forename: Frank
authors.initials: F
authors.lastname: DeStefano
mesh_terms: D000293:Adolescent; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data*; D000368:Aged; D002648:Child; D002675:Child, Preschool; D057225:Data Mining; D005260:Female; D006801:Humans; D007223:Infant; D053118:Influenza A Virus, H1N1 Subtype; D007252:Influenza Vaccines / Q000009:adverse effects*; D007251:Influenza, Human / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing / Q000379:methods; D014481:United States; D014611:Vaccination / Q000009:adverse effects / Q000706:statistics & numerical data; D055815:Young Adult
chemical_list: D007252:Influenza Vaccines